Journal of Dermatology最新文献

{"title":"Efficacy and Safety of the Topical Gene Therapy Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Study of Japanese Subjects With Dystrophic Epidermolysis Bullosa","authors":"Ken Natsuga,&nbsp;Daisuke Tsuruta,&nbsp;Shota Takashima,&nbsp;Chiharu Tateishi,&nbsp;Masaaki Takatoku,&nbsp;Brittani Agostini,&nbsp;Sarrah Mailliard,&nbsp;Nicholas J. Reitze,&nbsp;Rebecca T. Beacham,&nbsp;Alexia M. Cardiges,&nbsp;Michael J. Johnston,&nbsp;Ramakrishna Edukulla,&nbsp;Suma M. Krishnan","doi":"10.1111/1346-8138.17863","DOIUrl":"10.1111/1346-8138.17863","url":null,"abstract":"<p>Dystrophic epidermolysis bullosa (DEB) patients have pathogenic variants in <i>COL7A1</i>, leading to skin fragility, blistering, and scarring. Beremagene geperpavec-svdt (B-VEC) is a replication-defective herpes simplex virus type 1 (HSV-1)-based gene therapy vector administered topically to deliver functional <i>COL7A1</i> to DEB wounds. In a United States (US) Phase 3 study, B-VEC significantly improved wound healing at 3 and 6 months compared to placebo, and in a US open-label extension (OLE) study, weekly B-VEC administration was well tolerated for up to 112 weeks. The present study was conducted to confirm the efficacy and safety of B-VEC in a cohort of Japanese DEB patients receiving weekly B-VEC treatment (4.0 × 10⁹ plaque forming units (PFU)/mL) for 52 weeks. Wound healing assessments were conducted on a Primary Wound at visits corresponding to Month 3 (the secondary efficacy endpoint), Month 6 (the primary efficacy endpoint), and Months 9 and 12 (exploratory durability endpoints). Patient-reported outcome (PRO) measures were employed as exploratory analyses of efficacy. Safety was assessed by adverse events (AEs) and clinical laboratory tests. Five subjects enrolled in the study; one discontinued due to challenges with following wound dressing disposal guidelines. The study met its primary and secondary efficacy endpoints with 100% of Primary Wounds demonstrating complete closure at Months 6 and 3, respectively; durable complete closure was observed in 3/4 (75%) of wounds at Months 9 and 12. PROs indicated decreased pain, improvement in skin-specific quality of life, and moderate to high treatment satisfaction. Four subjects reported ten AEs; all were assessed as mild or moderate in severity and unrelated to treatment by Investigators. None were serious, severe, or led to treatment/study discontinuation. The results of the Japan OLE study are in agreement with the US Phase 3 and OLE studies, demonstrating the efficacy and safety of B-VEC in Japanese patients with DEB.</p><p><b>Trial Registration:</b> Japan Registry of Clinical Trials: jRCT2053230075</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"1494-1502"},"PeriodicalIF":2.7,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17863","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144644490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disease Impact and Burden of Psoriasis Vulgaris in Visible Body Areas in Japan: A Qualitative Study","authors":"Koki Endo,&nbsp;Yuko Higaki,&nbsp;Ami Cho,&nbsp;Yoshiyuki Sugimoto,&nbsp;Kyoko Ikumi,&nbsp;Miyu Okamura,&nbsp;Moe Matsuo,&nbsp;Yayoi Tada","doi":"10.1111/1346-8138.17835","DOIUrl":"https://doi.org/10.1111/1346-8138.17835","url":null,"abstract":"<p>International studies describe considerable multi-faceted burdens for patients living with psoriasis vulgaris. However, there is few research on the experience in the life of patients with psoriasis vulgaris in Japan, particularly regarding psychosocial impacts when symptoms are visible parts of their body. A qualitative descriptive study using semi-structured one-on-one interviews was conducted with 23 patients. Interviews focused on the impact of psoriasis vulgaris on motivation, daily life, social interactions, life course decisions, and psychological burdens, and the transcripts were distilled into discrete qualitative concepts. Common concepts elicited from patients included changes in clothing preferences and reluctance to engage in public activities like visiting public baths and pools due to their visible skin lesions. Many patients reported encountering misconceptions about their condition, which impacted their social relationships. Notably, effective treatment led to positive life changes. The adoption of a more patient-centered treatment design may reduce the unique psychological challenges faced by individuals living with visible psoriasis vulgaris symptoms and increase their quality of life.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 9","pages":"1439-1446"},"PeriodicalIF":2.7,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17835","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144999143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iatrogenic Kaposi's Sarcoma in a Patient With Chronic Kidney Disease","authors":"Haruna Kimura,&nbsp;Akito Hasegawa,&nbsp;Toru Kawai,&nbsp;Kohei Ogawa,&nbsp;Riichiro Abe","doi":"10.1111/1346-8138.17862","DOIUrl":"10.1111/1346-8138.17862","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"e912-e914"},"PeriodicalIF":2.7,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144639180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Etanercept in Japanese Patients With Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Unresponsive to Systemic Steroid Therapy: A Multicenter, Open-Label, Single-Arm Study","authors":"Haruna Kimura,&nbsp;Mahoko Oginezawa,&nbsp;Natsumi Hama,&nbsp;Yuko Watanabe,&nbsp;Yukie Yamaguchi,&nbsp;Saeko Nakajima,&nbsp;Hideaki Watanabe,&nbsp;Riichiro Abe","doi":"10.1111/1346-8138.17860","DOIUrl":"10.1111/1346-8138.17860","url":null,"abstract":"<div>\u0000 \u0000 <p>Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe, life-threatening cutaneous adverse reactions that have limited treatment options when systemic corticosteroids prove ineffective. To assess the efficacy and safety of etanercept in patients with SJS/TEN who failed to respond adequately to systemic corticosteroid therapy. In this multicenter, open-label, single-arm study conducted in Japan, patients with SJS or TEN unresponsive to ≥ 2 days of systemic corticosteroids (prednisolone-equivalent ≥ 20 mg/day) were enrolled. Etanercept 50 mg was administered subcutaneously on Day 1, with additional doses on Days 8 and 15 if re-epithelialization remained incomplete. The primary outcome was time to complete re-epithelialization. Secondary endpoints included time to cessation of skin progression, hospitalization duration, disease severity scores, ocular complications, and safety outcomes. Eight Japanese patients (mean age: 63.4 years; SJS: 5, TEN: 3) were treated. The median time to complete re-epithelialization was 10 days (95% Confidence interval: 6.0–20.0). All patients achieved re-epithelialization within 29 days. The mean time to cessation of skin progression was 4.0 days, and the mean hospitalization duration was 19.3 days. No deaths occurred. Adverse events were reported in six patients (75%), including two serious infections (cytomegalovirus and cryptococcosis). However, none were judged related to etanercept. No treatment discontinuations occurred. Etanercept could be an effective and safe treatment option for patients with SJS/TEN unresponsive to systemic corticosteroids. These findings warrant validation in larger, controlled studies.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"1536-1544"},"PeriodicalIF":2.7,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144628461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acral Melanoma Successfully Treated With Dacarbazine Following Anti-PD-1 Antibody Therapy: A Case Report and Literature Review","authors":"Iemitsu Matsuda,&nbsp;Junji Kato,&nbsp;Chika Fujie,&nbsp;Kohei Horimoto,&nbsp;Yoshiyuki Matsui,&nbsp;Midori Narasaki,&nbsp;Yusuke Otaki,&nbsp;Minami Takahashi,&nbsp;Manaka Kobayashi,&nbsp;Hisashi Uhara","doi":"10.1111/1346-8138.17861","DOIUrl":"10.1111/1346-8138.17861","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 9","pages":"e856-e858"},"PeriodicalIF":2.7,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144628459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of the Incidence and Severity of Cellulitis During the COVID-19 Pandemic in Japan","authors":"Tomoyo Sato,&nbsp;Kazuhiro Abe,&nbsp;Atsushi Miyawaki,&nbsp;Hirofumi Ohnishi,&nbsp;Hisashi Uhara","doi":"10.1111/1346-8138.17853","DOIUrl":"10.1111/1346-8138.17853","url":null,"abstract":"<p>During the COVID-19 pandemic, a decline in various infectious disease cases was observed. However, changes in dermatological infectious diseases, particularly cellulitis, and the potential impact of delayed consultations on severe cases have not been fully explored. To investigate changes in the number of cellulitis patients and severe cases during the COVID-19 pandemic. We employed a difference-in-differences (DID) design using a de-identified claims database from 242 acute-care hospitals across Japan to compare the pre-pandemic period (January 1, 2015, to December 31, 2019) with the pandemic period (January 1, 2020, to December 31, 2020). The national state of emergency, declared by the Japanese government in April 2020 in response to COVID-19, was treated as an exogenous shock. The study analyzed outpatient, inpatient, and total cases, sepsis and bacteremia complications, ambulance transport rates, length of hospital stay, and inpatient comorbidities. A total of 28 673 cellulitis cases were analyzed (24 256 from 2015 to 2019; 4417 in 2020). Severity indicators included hospitalization (8.2%), sepsis (4.1%), bacteremia (1.7%), and ambulance transport (17.0%). In the DID analysis, a significant decrease was observed in total cellulitis cases (incidence rate ratio [IRR]: 0.91; 95% confidence interval [CI]: 0.85–0.97), outpatient cases (IRR: 0.92; 95% CI: 0.86–0.98), and inpatient cases (IRR: 0.81; 95% CI: 0.66–0.99). No significant differences were found in sepsis (IRR: 0.53; 95% CI: 0.26–1.10), bacteremia (IRR: 0.73; 95% CI: 0.19–2.86), ambulance transport (IRR: 0.81; 95% CI: 0.50–1.29), or length of hospital stay (IRR: 0.83; 95% CI: 0.66–1.03). During the pandemic, the number of cellulitis cases treated in Japanese acute-care hospitals decreased without a significant rise in severe cases, suggesting the possibility that avoidance of medical consultations may not have worsened outcomes. Pandemic-related behavioral changes may have contributed to the reduced incidence.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"1512-1518"},"PeriodicalIF":2.7,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17853","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144628460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coexisting Faun-Tail Nevus and Aplasia Cutis Without Dysraphism: A Rare Association","authors":"Sonika Garg,&nbsp;Lekshmi P. Kumar,&nbsp;Vishal Gaurav","doi":"10.1111/1346-8138.17865","DOIUrl":"10.1111/1346-8138.17865","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 8","pages":"e698-e699"},"PeriodicalIF":2.7,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brain Metastasis From Angiosarcoma of the Scalp: Report of Three Cases","authors":"Mami Kudo,&nbsp;Riku Shirato,&nbsp;Teruki Yanagi,&nbsp;Wataru Yamagata,&nbsp;Akira Yogi,&nbsp;Aoi Ohira,&nbsp;Ririko Iwamoto,&nbsp;Kenzo Takahashi","doi":"10.1111/1346-8138.17858","DOIUrl":"https://doi.org/10.1111/1346-8138.17858","url":null,"abstract":"<div>\u0000 \u0000 <p>Brain metastasis from cutaneous angiosarcoma of the scalp is rare, and the characteristics and optimal treatment remain poorly understood. Herein, we report three cases of brain metastasis originating from cAS of the scalp. Case 1: An 81-year-old male developed lung metastasis 2.5 years after initial diagnosis, followed by brain metastasis 1 year later. He passed away 1 month after the detection of brain metastasis. Case 2: A 66-year-old male presented with lung and cervical lymph node metastases at the time of initial diagnosis. Brain metastasis was identified 5 months later after the onset of dizziness, and he passed away 2 months thereafter. Case 3: A 68-year-old male developed lung metastasis 7 months after initial diagnosis. Brain metastasis was detected 1 month later via computed tomography (CT). Palliative radiation therapy (30 Gy) led to a reduction in the size of the metastatic brain lesion; however, he passed away 2 months later. In each case, plain CT scans showed multiple high-density areas. The period from brain metastasis detection to death was uniformly short, within 2 months. These findings suggest that brain metastasis in cutaneous angiosarcoma of the scalp is associated with a poor prognosis.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 9","pages":"1456-1460"},"PeriodicalIF":2.7,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144999081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating Interleukin-6 and Janus Kinase 2 DNA Copies in Serum Cell-Free DNA Are Elevated in Patients With Systemic Sclerosis","authors":"Hitomi Matsunaga-Nakashima,&nbsp;Soichiro Sawamura,&nbsp;Tselmeg Mijiddorj Myangat,&nbsp;Tamami Yamamoto,&nbsp;Shuichi Shimada,&nbsp;Kayo Kashiwada-Nakamura,&nbsp;Ikko Kajihara,&nbsp;Kastunari Makino,&nbsp;Kenyu Hashimoto,&nbsp;Shinichi Masuguchi,&nbsp;Satoshi Fukushima","doi":"10.1111/1346-8138.17857","DOIUrl":"10.1111/1346-8138.17857","url":null,"abstract":"<div>\u0000 \u0000 <p>Recently, cell-free DNA (cfDNA) has gained attention as a diagnostic and prognostic biomarker for various conditions, including autoimmune and inflammatory skin diseases. However, reports of cfDNA use in patients with systemic sclerosis (SSc) are limited. The purpose of this study was to investigate the clinical significance of cfDNA in patients with SSc and assess the circulating DNA levels of key cytokines associated with SSc fibrosis. Serum samples were obtained from 64 patients with SSc, 9 with very early SSc, and 20 healthy controls (HC). Circulating DNA copies were quantified using droplet digital polymerase chain reaction analysis. The DNA copies of interleukin <i>(IL)-6</i>, <i>IL-8</i>, Janus kinase 2 (<i>JAK2</i>), and connective tissue growth factor were significantly higher in patients with SSc than in the HCs. Although not statistically significant, circulating <i>IL</i>-6 DNA copies were higher in patients with SSc than in patients with very early SSc. Receiver operating characteristic analysis indicated that <i>IL-6</i> DNA copies could distinguish patients with SSc from both the HCs and patients with very early SSc (area under the curve &gt; 0.7 in both cases). Disease type dcSSc and reduced %FVC were significant independent predictors of higher circulating <i>IL-6</i> and <i>JAK2</i> DNA copies in multivariate logistic regression analysis. cfDNA, including circulating <i>IL-6</i> and <i>JAK2</i> DNA in sera, may serve as valuable indicators for diagnosis and fibrosis progression in patients with SSc.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 9","pages":"1430-1438"},"PeriodicalIF":2.7,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144610830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased Risk of Chronic Kidney Disease in Atopic Dermatitis: A Nationwide, Population-Based Cohort Analysis","authors":"Hsi-Chih Chen,&nbsp;Yong-Chen Chen,&nbsp;Min-Hua Chuang,&nbsp;Wu-Chien Chien,&nbsp;Tsung-Kun Lin,&nbsp;Ting-Hsien Kao,&nbsp;Yu-Ching Chou,&nbsp;Chia-Chao Wu,&nbsp;Chien-An Sun","doi":"10.1111/1346-8138.17841","DOIUrl":"10.1111/1346-8138.17841","url":null,"abstract":"<div>\u0000 \u0000 <p>The association between atopic dermatitis (AD) and the progression of chronic kidney disease (CKD) has been a subject of scientific discussion with limited comprehensive data. A nationwide longitudinal study was conducted to investigate the correlation between AD and the risk of CKD. Utilizing Taiwan's National Health Insurance Research Database, a total of 15 179 individuals with AD (the exposed cohort) were identified and compared with 60 716 age and sex-matched individuals without AD (the comparison cohort) during the period from years 2000 to 2008. Follow-up time was recorded since the date of entry into the cohort until the occurrence of CKD, death, or the end of the study on December 31, 2013, whichever occurred first. Odds ratios (ORs) and accompanying 95% confidence intervals (CIs) derived from the logistic regression models were used to estimate the association between AD and CKD risk. Compared with the non-AD comparison cohort, patients with AD had elevated risk of CKD after adjustment for potential confounders (adjusted OR, 1.30; 95% CI, 1.21–1.40). A association between AD and increased risk of CKD was evident in both men and women and in all age groups. Furthermore, a trend with a increase in ORs with increasing frequency of clinical visits for AD was noted (<i>p</i> = 0.002). This population-based cohort study demonstrated that AD is related to a heightened risk of CKD within an Asian population. The clinical implications of the present study merit further investigations.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 9","pages":"1424-1429"},"PeriodicalIF":2.7,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}